Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, November 10, 2022
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
Dane Leone Maintained (XLO) at Buy with Decreased Target to $13 on, Nov 10th, 2022
Dane Leone of Raymond James, Maintained "Xilio Therapeutics, Inc." (XLO) at Buy with Decreased Target from $31 to $13 on, Nov 10th, 2022.
Dane has made no other calls on XLO in the last 4 months.
There is 1 other peer that has a rating on XLO. Out of the 1 peers that are also analyzing XLO, 0 agree with Dane's Rating of Hold.
This is the rating of the analyst that currently disagrees with Dane
- Michael Ulz of "Morgan Stanley" Maintained at Buy with Decreased Target to $20 on, Wednesday, August 10th, 2022
